Ginsenoside Rb1 enhances atherosclerotic plaque stability by skewing macrophages to the M2 phenotype

Xue Zhang a, b, #, Ming-hao Liu a, #, Lei Qiao a, Xin-yu Zhang a, Xiao-ling Liu a, Mei Dong a, Hong-yan Dai b, Mei Ni a, Xiao-rong Luan a, Jun Guan b, *, Hui-xia Lu a, *

a The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health; The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine; Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China
b Department of Cardiology, Qingdao Municipal Hospital, Qingdao, China

Received: November 10, 2016; Accepted: July 3, 2017

Abstract

Atherosclerosis (AS) is characterized as progressive arterial plaque, which is easy to rupture under low stability. Macrophage polarization and inflammation response plays an important role in regulating plaque stability. Ginsenoside Rb1 (Rb1), one of the main active principles of Panax Ginseng, has been found powerful potential in alleviating inflammatory response. However, whether Rb1 could exert protective effects on AS plaque stability remains unclear. This study investigated the role of Rb1 on macrophage polarization and atherosclerotic plaque stability using primary peritoneal macrophages isolated from C57BL/6 mice and AS model in ApoE−/− mice. In vitro, Rb1 treatment promoted the expression of arginase-I (Arg-I) and macrophage mannose receptor (CD206), two classic M2 macrophages markers, while the expression of iNOS (M1 macrophages) was decreased. Rb1 increased interleukin-4 (IL-4) and interleukin-13 (IL-13) secretion in supernatant and promoted STAT6 phosphorylation. IL-4 and/or IL-13 neutralizing antibodies and leflunomide, a STAT6 inhibitor attenuated the up-regulation of M2 markers induced by Rb1. In vivo, the administration of Rb1 promoted atherosclerotic lesion stability, accompanied by increased M2 macrophage phenotype and reduced MMP-9 staining. These data suggested that Rb1 enhanced atherosclerotic plaque stability through promoting anti-inflammatory M2 macrophage polarization, which is achieved partly by increasing the production of IL-4 and/or IL-13 and STAT6 phosphorylation. Our study provides new evidence for possibility of Rb1 in prevention and treatment of atherosclerosis.

Keywords: Ginsenoside Rb1 • M2 macrophages • inflammation • atherosclerotic plaque stability

Introduction

Coronary artery disease (CAD) has become the global health problem in both developed and developing countries. Atherosclerotic plaque has been proved pathological basis. With progressive growth of atherosclerosis (AS), plaques become vulnerable and are easy to rupture [1, 2]. Efforts to understand the dynamic change in plaque help us seek for new therapy to stabilize the AS plaque [3, 4]. It is well established that macrophages play a pivotal role in the whole AS progression via infiltration and switch of population, which has been termed as ‘macrophage polarization’ in recent literatures [5, 6]. Macrophage can differentiate into two antagonistic subtypes: classically activated by interferon-gamma (IFN-γ) or lipopolysaccharide (LPS), known as M1; or alternatively activated by interleukin (IL)-13 or IL-4, known as M2 [7]. The two phenotypes of macrophage play a different role in inflammation through production of pro-inflammatory or anti-inflammatory cytokines, depending on micro-environmental stimuli [8–11]. Pro-inflammatory M1 macrophages could lead to a more vulnerable plaque while anti-inflammatory M2 macrophages have protective effects [12]. Therefore, promoting M2 macrophage polarization may provide a new approach to alleviate inflammation and increase AS plaque stability.

Panax Ginseng has been proved one of the greatest medical ingredients in traditional Chinese medicine through thousands of years. Active components of ginseng have been separated and identified recently. Ginsenoside Rb1 is one of the main active components
Materials and methods

Ethics approval

The experiment protocols complied with the Animal Management Rules of the Chinese Ministry of Health (document no. 55, 2001) and conform to the NIH guidelines (the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health; NIH Publication No. 85-23, revised 1996). Ethics committee of Oulu Hospital of Shandong University has approved all the animal experiments.

Isolation of peritoneal macrophages

C57BL/6 mice (8-10 weeks old) were injected intraperitoneally with 1 ml 3% Thioglycolate Broth (Fluka, Shanghai, China) to recruit macrophages to peritoneal cavity according to previous study [16]. Three days post-injection, peritoneal macrophages were collected by mouse peritoneal cavity using cold sterile PBS. The cell pellets were obtained after centrifugation at 800 r.p.m. for 5 min. The cells were incubated in 1640 RPMI (Beyotime Biotechnology, Shanghai, China) supplemented with 10% FBS (Gibco, ThermoFisher Scientific, Shanghai, China) and 1% antibiotics (Gibco®) for 3 hrs and washed three times to remove non-adherent cells.

Cell culture and treatment

Peritoneal macrophages were pre-treated with indicated concentrations of Ginsenoside Rb1 (Fleton Natural Products, Chengdu, Sichuan, China) for 1 h prior to the incubation of lipopolysaccharide (LPS; Sigma-Aldrich, Merck, Shanghai, China, 1 μg/ml) for indicated time period. To examine the effects of IL-4 (3 μg/ml; eBioscience, Shanghai, China) and IL-13 (3 μg/ml; eBioscience, ThermoFisher Scientific, Shanghai, China) neutralizing antibodies, the two antibodies were added in medium at the same time with Rb1 (20 μM) for indicated period of time. To address the role of signal factor STAT6, cells were pre-treated with 50 μM lefunomide (Enzo Life Sciences, Farmingdale, NY, USA), a STAT6 inhibitor, for 12 hrs before exposure to Rb1.

Western blot analysis

Peritoneal macrophages were washed with ice-cold PBS and homogenized on ice using RIPA lysis buffer (Beyotime) supplemented with complete protease inhibitor (Beyotime). Samples were loaded on 10% SDS-PAGE and transferred onto PVDF membranes (Bio-Rad, Shanghai, China). Membranes were blocked with 5% non-fat dry milk and incubated with primary antibodies against iNOS (ab129372; Abcam), Arg-I (ab91279; Abcam), p-STAT6 (ab54461; Abcam), STAT6 (ab32520; Abcam), respectively. β-actin was used as control. The intensities of the corresponding protein bands were evaluated by densitometry via Image J (National Institutes of Health, USA). Protein expression was assessed relative to β-actin or indicated protein.

Flow cytometry

RAW264.7 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco®) with additional10% foetal calf serum (Gibco®) at 37°C humidified incubator under 5% CO2. RAW264.7 cells were incubated in the presence or absence of various concentrations of Rb1 that was always added 1 hr prior to LPS (1 μg/ml) treatment. RAW264.7 cells were washed, blocked and then incubated for 30 min. with APC-conjugated anti-mouse C0206 (141708; Biolegend, San Diego, CA, USA) using the appropriate isotype controls. The stained cells were acquired on a BD FACS Caliber flow cytometer (BD Biosciences, San Jose, CA, USA) and analysed with FlowJo v9.0 software (Tree Star, Inc., FlowJo v9.0, Ashland, Or, USA).

Enzyme-linked immunosorbent assays (ELISA)

Concentration of MMP-9, IL-10, IL-4 and IL-13 in culture supernatants was measured by ELISA kit (eBioscience®) following the manufacturer’s protocol.

Animal feeding and treatment

A total of 20 ApoE−/− mice (male, 8 weeks old) were applied. The mice were obtained from Charles River Laboratories (Beijing, China). All ApoE−/− mice were allowed to acclimatize for 1 week and fed a high-fat diet (0.25% cholesterol and 15% cocoa butter) for 22 weeks. Then, mice were randomly divided into two groups (10 mice per group). In the Rb1 group, the mice were injected with Rb1 (50 mg/kg) daily for 7 weeks; and in the control group, mice were injected intraperitoneally with sterile PBS.

Immunofluorescence and Immunohistochemistry

All the mice were euthanized. Hearts with attached aortic roots were harvested quickly frozen in OCT and sectioned (5 μm thick). Further immunohistochemical and immunofluorescent analyses were conducted as described below. Mouse aortic sinus cryosections were stained with anti-inducible nitric oxide synthase antibody [NOS] (ab178945; Abcam), anti-Arginase antibody [Arg-I] (ab91279; Abcam), anti-alpha smooth muscle Actin antibody [SMA] (ab5694; Abcam) and anti-Monocyte/Macrophage antibody [MOMA-2] (MCA519G; AbD, UK), MMP-9 (ab38898; Abcam). Morphometric analysis was performed on digitized images of intimal lesions and MOMA-2-immunostained areas using

Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
phage polarization through increasing secreting IL-4 and/or IL-13, we investigated whether Rb1 induced M2 macrophage polarization partly through increasing secretion of IL-4 and IL-13.

Results

Rb1 promoted M2 macrophages polarization

To explore the role of Rb1 in modulation of macrophage phenotype in vitro, the expression of iNOS (M1 marker) and Arg-1 (M2 marker) was detected in LPS-stimulated peritoneal macrophages with or without treatment with Rb1. We found that Rb1 inhibited the expression of iNOS in a dose-dependent manner; meanwhile, Arg-1 level was increased at the dose of 20 and 40 μM, compared with the LPS-stimulated macrophages (Fig. 1A and B), without increasing cell mortality with CCK-8 test (Fig. S1A and B). In addition, the percentage of M2 phenotype (CD206+) cells of Rb1 group was much higher than that of the LPS-stimulated group by flow cytometric analysis (Fig. 1C and D). Besides, we chose the dose of 20 μM in the following experiments.

Correspondingly, Rb1 suppressed the inflammatory response of macrophages induced by LPS as demonstrated by a significant decrease of pro-inflammatory cytokine levels of MMP-9 and an increase of anti-inflammatory cytokines of IL-10 (Fig. 1E). Therefore, these results suggested that Rb1 could skew macrophages to anti-inflammatory M2 phenotype in vitro.

IL-4 and IL-13 were involved in Rb1-mediated macrophage polarization

IL-4 and IL-13 are known as the prototypical direct inducers of M2 macrophage [19, 20]. To investigate whether Rb1 induced M2 macrophage polarization through increasing secreting IL-4 and/or IL-13, we measured IL-4 and IL-13 protein levels in supernatant. Our results showed that both the amount of IL-4 and IL-13 in supernatant was significantly increased after treatment with Rb1 for 24 hrs (Fig. 2A). These results indicated that Rb1 promoted IL-4 and IL-13 secretion in macrophages.

To further explore the role of IL-4 and/or IL-13 in Rb1-induced M2 macrophage polarization, LPS-stimulated macrophages were cultured in the presence or absence of neutralizing IL-4 and/or IL-13 antibodies, respectively. Notably, the effects of Rb1 on M2 macrophage polarization were attenuated with the treatment of IL-4 or IL-13 neutralizing antibodies (Fig. 2B). These results indicated that Rb1 induced M2 macrophage polarization partly through increasing secretion of IL-4 and IL-13.

Rb1 induced M2 macrophage polarization through STAT6-dependent pathway

Previous studies showed that IL-4 and IL-13 induced M2 macrophages polarization through activation of signal transducer and activator of transcription factor 6 (STAT6) [17]. To investigate whether STAT6 was involved in Rb1-induced M2 macrophage polarization, we detected STAT6 phosphorylation level in mouse peritoneal macrophages after Rb1 treatment. The results showed that the level of p-STAT6/STAT6 after treatment of 20 μM Rb1 was significantly higher than that in the LPS-stimulated group (Fig. 3A and B). Furthermore, leflunomide, a STAT6 inhibitor, markedly reverted M2 macrophage polarization induced by Rb1 (Fig. 3C and D). These results indicated that Rb1 induced M2 macrophage polarization by producing IL-4 and IL-13 and through STAT6-dependent pathway.

Rb1 increased plaque stability in ApoE−/− mice

As we found Rb1 promoted M2 macrophages polarization in vitro, we next validated the effect of Rb1 on arterial inflammation and atherosclerotic plaque stability in vivo. Atherosclerotic vulnerable plaque is characterized by a mass of macrophage infiltration and lipid accumulation, as well as a thin cap with less collagen and smooth muscle cell (SMCs) [21, 22]. Our results showed that the morphology of plaque in control group coincides with the feature of typical vulnerable plaque. Composition of plaque has obviously changed after Rb1 treatment, in which the content of lipids and macrophages was significantly decreased, but that of collagen and SMCs was significantly increased after treatment with Rb1 (Fig. 4A-E). Consequently, the vulnerability index of plaque in Rb1-treated mice was significantly reduced compared to the control group (Fig. 4F). Besides, staining for matrix degrading proteases-9 (MMP-9), a pro-atherosclerosis cytokine secreted by macrophages, was also decreased significantly in atherosclerotic lesions of mice in the Rb1 group (Fig. 4G and H). These results indicated that Rb1 treatment enhanced atherosclerotic plaque stability.

We have tested respective components of blood lipid in both groups (Table S1). Although there was a tendency of lower LDL-

Statistical analysis

All data were representative of at least three different experiments. Statistical analysis was performed using Graphpad Prism 6.0, La Jolla, CA, USA. The values were presented as mean ± S.D. Student’s t-test was used for two-group comparisons. One-way ANOVA was used for multi-group comparisons following Turkey’s test. Power analysis was applied to determine the difference of blood lipid between two groups. P < 0.05 was considered significant.
c, HDL-c and triglyceride in Rb1 treatment group, there was no significant difference between two groups. A post hoc power analysis has been conducted and the power of test is weak. Therefore, we cannot clearly conclude that Rb1 has definite effects on blood lipid so far.

**Rb1 treatment promoted M2 macrophage polarization in atherosclerotic plaque**

To investigate whether macrophage polarization switch was involved in the role of Rb1 on atherosclerosis, immunofluorescent analysis of
Fig. 3 Rb1 induced macrophage M2 polarization through STAT6-dependent pathway. (A) Representative immunoblots of the p-STAT6 in peritoneal macrophages cells treated by Rb1. (B) Statistics of immunoblots presented as p-STAT6 relative to the STAT6 level. (C) Representative immunoblots of the iNOS and Arg-I protein in peritoneal macrophages cells treated by Rb1 for 24 hrs with or without the STAT6 inhibitor. (D) Statistics of iNOS and Arg-I expression relative to the β-actin level. Data are presented as means ± S.D.; *P < 0.05, compared to LPS-treated group; #P < 0.05, compared to LPS+Rb1-treated group; & P < 0.05, compared to control group; n = 3.

Fig. 4 Rb1 obviously increased AS plaque stability of atherosclerotic ApoE−/− mice. (A)(B)(C) Immuno histochemical staining of Oil red-O staining of lipids, MOMA-2 (macrophage marker), smooth muscle cells. (D) Representative images of Sirius Red-staining for quantification of the lesion collagen content. (E) Statistics of (A)–(D) measured as area ratio. (F) Vulnerability index of plaque in corresponding groups calculated as (lipid deposit% + macrophages%) / (collagen fibres% + SMCs%). Data are means ± S.D.; Scale bar: 100 μm. *P < 0.05. (G) (H) Representative immunohistochemistry and statistics of MMP-9 expression. Quantification of the MMP-9 positive staining area expressed as percentage of total lesion area. Data are presented as means ± S.D.; Scale bar: 20 μm. *P < 0.05; n = 6.
Fig. 5 Effects of Rb1 on macrophage polarization in atherosclerotic lesions of ApoE−/− mice. (A, B) Representative images of MOMA-2+iNOS+ and MOMA-2+Arg-1+ macrophages in situ in corresponding groups (NC: control group; Rb1: Rb1 treatment group). (C, D) Statistics of the number of MOMA-2+iNOS+ and MOMA-2+Arg-1+ macrophages in atherosclerotic lesions in control and Rb1-treated ApoE−/− mice. Scale bar: 20 μm. *P < 0.05; n = 6. (E) Representative immunoblots of iNOS (M1 marker) and Arg-1 (M2 marker) in vivo. (F) Statistics of iNOS and Arg-1 expression relative to the β-actin level. Data are presented as means ± S.D.; *P < 0.05, compared to control group; n = 3.
INOS and Arg-I expression was applied to identify and evaluate, respectively, M1 and M2 macrophage (MOMA-2+ cells) in aortic root cryosections from Rb1 and control group. The number of MOMA-2+ INOS+ double positive macrophages (M1 macrophage) in atherosclerotic lesions was significantly decreased in the Rb1 group compared with the control group (Fig. 5A–D). Meanwhile, the number of double positive MOMA-2+Arg-I+ macrophages (M2 macrophage) was significantly increased in the atherosclerotic lesions of Rb1 group. Similar results were observed at the protein level of INOS and Arg-I in aortic lysates of both groups by Western blotting (Fig. 5E and F). These results suggested that Rb1 treatment skewed macrophages to M2 phenotype in atherosclerotic lesions.

Discussion

In this study, we confirmed that Rb1 promoted M2 macrophage polarization and restricted inflammatory response, which further contributed to enhance atherosclerotic plaque stability in ApoE−/− mice. The effects of Rb1 on macrophage M2 polarization were majorly achieved by increasing the production of IL-4 and IL-13 and successive STAT6 phosphorylation.

In recent decades, CAD has caused growing disability and mortality and has become one of the major health burdens [1]. Atherosclerosis is the major pathologic basis of CAD. Since Framingham heart study, we have stepped into an era to fight against with atherosclerosis. We have experienced great revolution in AS treatment, from Aspirin to statins, from medicine to stent, from treatment to prevention. Although the integrated treatment shows effective so far, there are still many serious problems we must face. Inevitable progression of AS plaque even under current therapy becomes one of the challenges, in which condition the plaque will become vulnerable and easy to rupture, causing acute coronary syndrome [1]. Therefore, approaches aiming at stabilizing and retarding the AS plaque have manifested effective and may become promising therapies [23–25].

With the AS progression, the plaques exhibit advanced features, with lipid accumulation, macrophages infiltration, covered with fibrous cap and smooth muscle cells [17, 21]. Studies have well demonstrated that balance of macrophage phenotypes M1 and M2 exerts potential effect on regulating AS plaque stability, with M1 leading to vulnerable plaque while M2 leading to stable plaque [26]. Therefore, strategies trying to promote M2 macrophage polarization may be available to stabilize plaques and limit AS progression [27, 28].

Traditional herbal medicine inspired us with newly discovered extracts. Ginsenoside Rb1 is a representative component of ginseng, an herbal medicine widely used in Eastern Asia. Previous studies have demonstrated its multifarious pharmacological effects, including anti-inflammation, anti-obesity and improving immunity [13, 14]. Recently, several studies have detected the effects of Rb1 in the cardiovascular system. Zheng and Cui showed, respectively, that Rb1 protected against cardiac remodelling and ischemia/reperfusion-induced myocardial injury, and Lan reported Rb1 could prevent homocysteine-induced endothelial dysfunction [13–15]. However, little is known about the role of Rb1 on atherosclerotic plaque stability.

Given the role of macrophage polarization in inflammatory response, we first investigated the effects of Rb1 on macrophage polarization. Our research verified that Rb1 induced a phenotypic alteration of macrophages from M2 to M1 in vitro, with consequential reduced pro-inflammatory cytokine (MMP-9) and enhanced anti-inflammatory cytokine (IL-10). These data suggested that Rb1 might alleviate inflammation by inducing M2 macrophages polarization.

Having proved that Rb1 could alleviate inflammation by skewing M2 macrophages polarization, we next determined the vascular-protective effect of Rb1. In the AS lesion from Rb1 treatment group, we observed a reduction of lipids accumulation and macrophage infiltration, as well as an increase of collagen and SMCs, which indicated a reduced vulnerability index of plaque. Consistent with in vitro, staining for MMP-9 was also decreased significantly in atherosclerotic lesions of mouse in the Rb1 group. To explore the mechanism by which Rb1 protected against atherosclerosis, we next investigated the M1/M2 macrophage polarization in atherosclerotic lesions. Not surprisingly, treatment with Rb1 promoted M2 macrophage polarization in atherosclerotic plaque. These results suggested that Rb1 treatment could increase AS plaque stability by promoting M2 macrophage polarization.

We further explored the underlying mechanisms by which Rb1 facilitated M2 macrophages polarization in vitro. IL-4 and IL-13 have been well demonstrated as classical and powerful M2 macrophage cytokines [19,20]. The pathways of the cytokines converge on signal transducer and activator of transcription 6 (STAT6) [26], which is critical for relative gene transcription and is considered as a potential new target in human atherosclerotic disease [29]. In our study, we found that Rb1 could effectively elevate both IL-4 and IL-13 secretion and promote STAT6 phosphorylation consecutively. This effect could be abrogated via adding either neutralizing antibodies or STAT6 inhibitor. Therefore, we concluded that Rb1 promoted M2 macrophage polarization by enhancing IL-4 and IL-13 secretion and through STAT6-dependent pathway.

There remains limitation in our work. It is reported that change in balance of blood lipids may affect macrophage polarization. In our work, although we did not reach a definite role of Rb1 on blood lipid, we manifested that Rb1 could regulate macrophage polarization directly in vitro. Till now, there is no consensus about Rb1 on blood lipid [30, 31], and it is promising to be further investigated.

Taken together, ginsenoside Rb1 protected against atherosclerosis by promoting M2 macrophage polarization and limiting intraplaque inflammatory response, which was achieved by increasing the production of IL-4 and IL-13 and STAT6 phosphorylation. Our study provides new experimental evidence for possibility of Rb1 in prevention and treatment of atherosclerosis.

Acknowledgements

Funding sources: This work was supported the National Natural Science Foundation of China (81270403, 81300217, 81400330), the Author of National Excellent Doctoral Dissertation of PR China (201181), the Program for HongKong scholar(2010104629), China Postdoctoral Science Foundation (2012M521353, 2014M551914), and the Natural Science Foundation of Shandong Province (2014ZRE27067, ZR2014CM010).
Conflict of interest

The authors declare no conflicts of interest.

Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article:

Reference

1. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868–74.
2. Sergin I, Razani B, et al. Self-eating in the plaque: what macrophage autophagy reveals about atherosclerosis. Trends Endocrinol Metab. 2014; 25: 225–34.
3. Breslow JL. Mouse models of atherosclerosis. Science. 1996; 272: 685–8.
4. Pasterkamp G, Schoneveld AH, Hijjnen DJ, et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteinases 1, 2 and 9 in the human coronary artery. Atherosclerosis. 2000; 150: 245–53.
5. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013; 13: 709–21.
6. Stoger JL, Gijbels MJ, van der Velden S, et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis. 2012; 225: 461–8.
7. Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014; 41:14–20.
8. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013; 496: 445–55.
9. Dall’Asta M, Derindal E, Ardigo D, et al. Macrophage polarization: the answer to the diet/inflammation conundrum? Nutr Metab Cardiovasc Dis. 2012; 22: 387–92.
10. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008; 8: 958–69.
11. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25: 677–86.
12. Hirata Y, Tabata M, Kurobe H, et al. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J Am Coll Cardiol. 2011; 58: 248–55.
13. Zhang XJ, He C, Tian K, et al. Ginsenoside Rb1 attenuates angiotensin II-induced abdominal aortic aneurysm through inactivation of the JNK and p38 signaling pathways. Vasc Pharmacol. 2015; 73: 86–95.
14. Yu J, Eto M, Akisita M, et al. Signaling pathway of nitric oxide production induced by ginsenoside Rb1 in human aortic endothelial cells: a possible involvement of androgen receptor. Biochem Biophys Res Commun. 2007; 353: 764–9.
15. Joh EH, Lee IA, Jung IH, Kim DH, Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation—the key step of inflammation. Biochem Pharmacol. 2011; 82: 278–86.
16. Chakraborty R, Bhatt KH, Sodhi A. Ultraviolet B induces high mobility group box 1 release from mouse peritoneal macrophages in vitro via caspase-1 mediated secretion pathway. Immunobiology. 2013; 218: 135–44.
17. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010; 32: 593–604.
18. Wen H, Liu M, Liu Z, et al. PDE5 improves atherosclerotic plaque stability by inhibiting macrophage inflammation response. Int J Cardiol. 2017; 235: 37–41.
19. Stein M, Keshav S, Harris N, et al. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage type. J Exp Med. 1992; 176: 287–92.
20. Doherty TM, Kastelein R, Menon S, et al. Modulation of murine macrophage function by IL-13. J Immunol. 1993; 151: 7151–60.
21. Nakashima Y, Plump AS, Raines EW, et al. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994; 14: 133–40.
22. See HS, Lombardi DM, Polinsky P, et al. Peripheral vascular stenosis in apolipoprotein E-deficient mice: potential roles of lipid deposition, medial atrophy, and adventitial inflammation. Arterioscler Thromb Vasc Biol. 1997; 17: 5993–601.
23. Wang XP, Zhang W, Liu XQ, et al. Arginase I enhances atherosclerotic plaque stabilization by inhibiting inflammation and promoting smooth muscle cell proliferation. Eur Heart J. 2014; 35: 911–9.
24. Park SJ, Lee KP, Kang S, et al. Sphingosine-1-phosphate induced anti-atherogenic and atheroprotective M2 macrophage polarization through IL-4. Cell Signal. 2014; 26: 2249–58.
25. El Hadri K, Mahmoud DF, Couchie D, et al. Thiorodoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis. Arterioscler Thromb Vasc Biol. 2012; 32: 1445–52.
26. Cardillo-Reis L, Gruber S, Schreier SM, et al. Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol Med. 2012; 4: 1072–86.
27. Wolfs IM, Donners MM, De Winther MP. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemost. 2011; 106: 763–71.
28. Liu G, Yang H. Modulation of macrophage activation and programming in immunity. J Cell Physiol. 2013; 228: 502–12.
29. Satterthwaite G, Francis SE, Suvarna K, et al. Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis. Am Heart J. 2005; 150: 488–99.
30. Yu X, Ye L, Zhang HG, et al. Ginsenoside Rb1 ameliorates liver fat accumulation by upregulating perilipin expression in adipose tissue of db/db obese mice. J Ginseng Res. 2015; 39: 199–205.
31. Xie X, Wang HT, Li CL, et al. Ginsenoside Rb1 protects PC12 cells against β-amyloid-induced cell injury. Mol Med Rep. 2010; 3: 635–9.

1997 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.